These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, Ma M, Nakagawa T, Kusaka H, Kim-Mitsuyama S. Cardiovasc Diabetol; 2014 Oct 26; 13():148. PubMed ID: 25344694 [Abstract] [Full Text] [Related]
7. Empagliflozin attenuates arrhythmogenesis in diabetic cardiomyopathy by normalizing intracellular Ca2+ handling in ventricular cardiomyocytes. Kadosaka T, Watanabe M, Natsui H, Koizumi T, Nakao M, Koya T, Hagiwara H, Kamada R, Temma T, Karube F, Fujiyama F, Anzai T. Am J Physiol Heart Circ Physiol; 2023 Mar 01; 324(3):H341-H354. PubMed ID: 36607794 [Abstract] [Full Text] [Related]